Trial Profile
A Multicenter, 3-Arm, Open-Label, Phase 2a Clinical Trial to Evaluate the Safety and Efficacy of TTAC-0001, a Fully Human Monoclonal Antibody in Patients with Recurrent Glioblastoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Apr 2022
Price :
$35
*
At a glance
- Drugs Olinvacimab (Primary)
- Indications Glioblastoma
- Focus Adverse reactions; Registrational
- Sponsors PharmAbcine
- 19 Nov 2019 According to a PharmAbcine media release, Olinbashimap was approved as a rare disease treatment (ODD) by the US FDA and Korea Food and Drug Administration as a result of Phase 2a for patients with recurrent glioblastoma in Australia.
- 01 Feb 2018 According to a PharmAbcine media release, final report of this trial will be available early in 2018
- 02 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology